GlassScriptPhysician profile
Michael James Banach
NPI 1710972310
$39,017.68
in general payments reported to CMS, 2019-2025
11 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,560 · 2020: $1,971 · 2021: $5,332 · 2022: $6,325 · 2023: $22K · 2024: $258 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $22K · Food and Beverage: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $22,172.33 |
| Food and Beverage | $657.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $38,152.91 | 2019-2023 | |
| Alcon Vision LLC | $205.60 | 2024-2025 | Clareon |
| Genentech USA, INC. | $167.96 | 2019-2025 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $125.00 | 2025 | |
| Abbvie INC. | $95.69 | 2022-2025 | Ozurdex |
| Bausch & Lomb Americas INC. | $87.64 | 2025 | Xipere |
| Regeneron Healthcare Solutions, INC. | $67.78 | 2022-2024 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $43.32 | 2019-2020 | |
| Biogen, INC. | $34.96 | 2022 | |
| Sandoz INC. | $18.68 | 2024 | Cimerli |
| Astellas Pharma US INC | $18.14 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$175,097.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Banach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.